Compare MDXG & POET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDXG | POET |
|---|---|---|
| Founded | 2006 | 1972 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 959.0M |
| IPO Year | 2007 | 2008 |
| Metric | MDXG | POET |
|---|---|---|
| Price | $4.55 | $7.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 746.7K | ★ 5.5M |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $418,630,000.00 | N/A |
| Revenue This Year | N/A | $2,939.08 |
| Revenue Next Year | $13.14 | $710.17 |
| P/E Ratio | $14.20 | ★ N/A |
| Revenue Growth | ★ 19.99 | N/A |
| 52 Week Low | $4.37 | $3.10 |
| 52 Week High | $8.13 | $9.41 |
| Indicator | MDXG | POET |
|---|---|---|
| Relative Strength Index (RSI) | 28.22 | 62.71 |
| Support Level | N/A | $6.88 |
| Resistance Level | $5.38 | $7.90 |
| Average True Range (ATR) | 0.19 | 0.52 |
| MACD | -0.03 | 0.15 |
| Stochastic Oscillator | 16.06 | 98.76 |
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.